Fineline Cube

Follow:
14409 Articles
CanSinoBIO Licenses ISL‑3C‑LNP Platform to PanRu Biotech – $100 M+ Deal to Accelerate mRNA Cancer Vaccines
CompanyDeals

CanSinoBIO Licenses ISL‑3C‑LNP Platform to PanRu Biotech – $100 M+ Deal to Accelerate mRNA Cancer Vaccines

Eisai China and Beckman Coulter Launch Alzheimer’s Blood‑Test Collaboration in Mainland China
CompanyDeals

Eisai China and Beckman Coulter Launch Alzheimer’s Blood‑Test Collaboration in Mainland China

Gilead Sciences’ Tro Delvy Fails to Meet Primary Endpoint in ASCENT‑07 Metastatic Breast Cancer Trial
CompanyDrug

Gilead Sciences’ Tro Delvy Fails to Meet Primary Endpoint in ASCENT‑07 Metastatic Breast Cancer Trial

Insilico Medicine & Eli Lilly Forge Strategic AI‑Driven Drug Discovery Alliance
CompanyDeals

Insilico Medicine & Eli Lilly Forge Strategic AI‑Driven Drug Discovery Alliance

SanegeneBio & Eli Lilly Sign Global Partnership to Advance RNAi Therapies for Metabolic Diseases
CompanyDeals

SanegeneBio & Eli Lilly Sign Global Partnership to Advance RNAi Therapies for Metabolic Diseases

DeliNova Raises Nearly RMB 60 Million in Seed & Angel Financing for In‑Vivo CAR‑T Platform
CompanyDeals

DeliNova Raises Nearly RMB 60 Million in Seed & Angel Financing for In‑Vivo CAR‑T Platform

Organon Acquires JADA System from Laborie for USD 465 Million
CompanyDeals

Organon Acquires JADA System from Laborie for USD 465 Million

HBM Holdings and Evinova Form AI‑Powered Biologic Therapy Collaboration
CompanyDeals

HBM Holdings and Evinova Form AI‑Powered Biologic Therapy Collaboration

Jiangsu Hengrui Pharmaceuticals Announces **HRS‑2430 Injection** Approval for Clinical Trials
CompanyDrug

Jiangsu Hengrui Pharmaceuticals Announces HRS‑2430 Injection Approval for Clinical Trials

National Health Commission’s Negative Behavior List for Medical Staff Internet‑Based Health Science Popularization (Trial)
Others

National Health Commission’s Negative Behavior List for Medical Staff Internet‑Based Health Science Popularization (Trial)

Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal
CompanyDeals

Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal

Aureka Biotechnologies Closes Multi‑Million‑Dollar Series A – Generative Antibody Platform Gains 5Y Capital & Qiming Backing
CompanyDeals

Aureka Biotechnologies Closes Multi‑Million‑Dollar Series A – Generative Antibody Platform Gains 5Y Capital & Qiming Backing